Literature DB >> 14983960

Determining the cause of death in randomized screening trial(s) for prostate cancer.

H J De Koning1, J Blom, J W Merkelbach, R Raaijmakers, H Verhaegen, P Van Vliet, V Nelen, J W W Coebergh, A Hermans, S Ciatto, T Mäkinen.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14983960     DOI： 10.1111/j.1465-5101.2003.04402.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  21 in total

1.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

2.  Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Authors:  Sigrid Carlsson; Melissa Assel; David Ulmert; Axel Gerdtsson; Jonas Hugosson; Andrew Vickers; Hans Lilja
Journal:  Eur Urol       Date:  2016-04-13       Impact factor: 20.096

3.  A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.

Authors:  Marco Zappa; Donella Puliti; Jonas Hugosson; Fritz H Schröder; Pim J van Leeuwen; Ries Kranse; Anssi Auvinen; Sigrid Carlsson; Maciej Kwiatkowski; Vera Nelen; Alvaro Paez Borda; Monique J Roobol; Arnauld Villers
Journal:  Eur Urol       Date:  2014-01-07       Impact factor: 20.096

4.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

5.  Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Carlotta Buzzoni; Anssi Auvinen; Monique J Roobol; Sigrid Carlsson; Sue M Moss; Donella Puliti; Harry J de Koning; Chris H Bangma; Louis J Denis; Maciej Kwiatkowski; Marcos Lujan; Vera Nelen; Alvaro Paez; Marco Randazzo; Xavier Rebillard; Teuvo L J Tammela; Arnauld Villers; Jonas Hugosson; Fritz H Schröder; Marco Zappa
Journal:  Eur Urol       Date:  2015-03-16       Impact factor: 20.096

6.  Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.

Authors:  Xiaoye Zhu; Pim J van Leeuwen; Erik Holmberg; Meelan Bul; Sigrid Carlsson; Fritz H Schröder; Monique J Roobol; Jonas Hugosson
Journal:  J Med Screen       Date:  2012-09       Impact factor: 2.136

7.  Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

Authors:  Anssi Auvinen; Sue M Moss; Teuvo L J Tammela; Kimmo Taari; Monique J Roobol; Fritz H Schröder; Chris H Bangma; Sigrid Carlsson; Gunnar Aus; Marco Zappa; Donella Puliti; Louis J Denis; Vera Nelen; Maciej Kwiatkowski; Marco Randazzo; Alvaro Paez; Marcos Lujan; Jonas Hugosson
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

8.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Esther I Verhoef; Ewout W Steyerberg; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2016-03-04       Impact factor: 7.842

9.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

10.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.